SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Nevertheless, it remains unclear whether the salutary actions of SGLT2 inhibitors against MASLD are mediated by promoting ketogenesis or through SGLT2-independent actions, as observed in the failing heart [108].